INKT — MiNK Therapeutics, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1840229 ·
Last close
$9.28
Market Cap
$47.67M
52W High
$16.93
52W Low
$8.48
ADV30
12,762
Next earnings
2026-11-11
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS). It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for autoimmune diseases, including in graft-versus-host disease prevention. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors; and C-Further for the development of PRAME-targeted iNKT cell therapy for pediatric cancers. The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 200,000 — -2,637,263 -2,552,283 8,243,058 7,470,862 24,494,476
Jun 2026 0 — -3,216,894 -3,128,201 9,615,242 8,806,977 23,643,538
Mar 2026 0 — -2,881,787 -2,742,368 10,376,972 9,525,676 23,062,961
Dec 2025 0 — -3,276,559 -2,602,103 14,238,842 13,360,340 28,466,501

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-6,830,483
Investing CF
—
Financing CF
$13,986,105
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.90
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-162,546,564
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-12,364,913
Pretax Income TTM
$-11,360,381
Interest Exp TTM
—
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$200,000
EBITDA
$-11,294,645
Free Cash Flow
$-6,208,454
Enterprise Value
$40,477,384
Total Cash
$7,470,862
Total Debt
$0
Shares Out
5,133,645
Trailing EPS
$-2.23
Book Value
$-3.19
ROE
—
ROA
-61.6%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -12,487,304 -12,494,260 14,238,842 28,466,501 -14,227,659 -5,925,168
Dec 2024 0 -10,650,239 -10,784,802 5,720,813 25,306,695 -19,585,882 -9,555,476
Dec 2023 0 -22,921,105 -22,457,859 4,552,281 22,607,730 -18,055,449 -15,762,512
Dec 2022 0 -30,949,278 -27,991,212 21,471,602 21,872,905 -401,303 -18,866,843
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$3,427,320
NetIncome TTM
$-11,360,381
OpCashFlow TTM
—
Assets (Latest)
$9,615,242
Forward EPS
$-0.72

Peers — same industry

TickerNameMarket CapLastDaily %
IMA ImageneBio, Inc. $48.58M $3.90 —
SGMOQ SANGAMO THERAPEUTICS, INC $45.57M $0.11 —
ELOX Eloxx Pharmaceuticals, Inc. $40.34M $11.74 —
OKYO OKYO Pharma Ltd $57.99M $1.11 —
PMCB PharmaCyte Biotech, Inc. $58.19M $5.42 —

News headlines (Yahoo Finance, 1h cache)

MiNK Therapeutics (INKT) Q3 2026 Earnings Call Transcript
2026-11-11 22:12 · Yahoo
MiNK Therapeutics, Inc. Q3 2026 Earnings Call Summary
2026-11-11 21:58 · Yahoo
MiNK Therapeutics Inc (INKT) Q1 2026 Earnings Call Highlights: Prolonged Survival in Gastric ...
2026-11-11 21:06 · Yahoo
What MiNK Therapeutics (INKT) Said on Its Q3 Earnings Call
2026-11-11 17:15 · Yahoo
MiNK Therapeutics, Inc. (INKT) Reports Q3 Loss, Beats Revenue Estimates
2026-11-11 15:25 · Yahoo
MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies
2026-11-11 12:30 · Yahoo
MiNK Therapeutics New Data Highlights Its Off-the-Shelf iNKT Cell Therapy Targets Two Key Mechanisms of Tumor Resistance Presented at the Society of Immunotherapy of Cancer (SITC 2026)
2026-11-06 14:48 · Yahoo
MiNK Therapeutics to Report Third Quarter 2026 Results and Outline Progress in Randomized Clinical Development and Scalable iNKT Cell Therapy
2026-11-02 21:35 · Yahoo
MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026
2026-10-02 13:00 · Yahoo
MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
2026-09-30 11:57 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.